Autres langues IDEAYA Biosciences, Inc.

Actions

IDYA

US45166A1025

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 29/04/2024			Varia. 5j.	Varia. 1 janv.
40,65 ^USD	+1,78 %		+8,14 %	+14,25 %

22/04	IDEAYA Biosciences, Inc. IDEAYA Biosciences annonce la sélection d'une dose d'expansion de phase 2 pour IDE397 en monothérapie dans le cancer squameux du poumon non à petites cellules avec délétion du MTAP	CI
21/03	IDEAYA BIOSCIENCES, INC. : Citigroup réitère son opinion positive sur le titre	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(4) - April 26, 2024	29/04
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	26/04
IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study	25/04
IDEAYA Biosciences Selects Move-Forward Expansion Dose for Mid-Stage Trial of IDE397 Monotherapy	22/04
IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer	22/04
IDEAYA Biosciences, Inc. Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer	22/04
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(4)	08/04
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	05/04
IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event	01/04
IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA in Patients with Endometrial Cancer	13/03
IDEAYA Biosciences, Merck Sign Deal to Evaluate IDE161 in Combination with Keytruda to Treat Endometrial Cancer Patients	12/03
IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer	12/03
IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer	12/03
IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events	04/03
IDEAYA Biosciences Q4 Loss Widens, Revenue Declines	20/02
Earnings Flash (IDYA) IDEAYA BIOSCIENCES Posts Q4 Revenue $3.9M	20/02
IDEAYA Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/02
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update	20/02
IDEAYA Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	20/02
Ideaya Biosciences Insider Sold Shares Worth $4,495,550, According to a Recent SEC Filing	12/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues IDEAYA Biosciences, Inc.

Actions

IDYA

US45166A1025

Autres langues

Filtres